Rigel Mulls Next Steps After Fostamatinib Fails In Kidney Disease
Rigel sees positive signs for Tavalisse in failed mid-stage study in autoimmune nephropathy, but investors don't share the optimism, sending the stock down almost 14% on the news.
You may also be interested in...
Alexion’s third deal this year brings privately held Syntimmune and its Phase Ib/IIa candidate for three IgG-mediated rare disorders, including warm autoimmune hemolytic anemia, for a $400m upfront price tag.
The latest drug development news and highlights from our US FDA Performance Tracker.
Another hectic 12 months are anticipated at the US FDA as it is set to give its verdict on no fewer than 40 products in 2018. Here Scrip takes a look at 10 of the more interesting candidates approaching the market for the first time.